Rationale Diagnostic Criteria of the Metabolic Syndrome
DOI:
https://doi.org/10.17140/DROJ-5-139Keywords:
Metabolic Syndrome Obesity, Waist circumference, Visceral fat, Adiponectin LeptinAbstract
Metabolic syndrome is a preceding risk of diabetes, hypertension and/or dyslipidemia, so the diagnosis of metabolic syndrome is important for further treatment. In 2005, the international diabetes foundation (IDF) reported a new diagnostic criterion of metabolic
syndrome, making abdominal obesity an essential factor required in the diagnosis. Waist circumference (WC) is used as a surrogate
marker of abdominal obesity, but it is defined based on the national cutoff point of each country. This study examined the validity
of diagnostic criteria ofmetabolic syndrome, especially focusing on the different criteria of WC, for international standardization.
Method We compared the efficacy of our previous weight-loss intervention by Japanese and IDF criteria by reanalyzing Saku control obesity program (SCOP). In IDF, the cutoff point of WC for men is 90 cm and 80 cm for women. On the contrary, the cutoff point of WC
is 85 cm for men and 90 cm for women in Japan. Factors for diagnosis was evaluated, and the prevalence of metabolic syndrome at
baseline and 1 year later was compared by the different diagnostic criteria. Result and Discussion In Japanese criteria, the rate of metabolic syndrome among men decreased from 100% to 97.3%, and among women 96.6% to 88.6%. However, when we applied the IDF criteria, the rate of metabolic syndrome among men decreased from 97.4% to 88.5%, and among women 100% to 100%. These results suggested that the prevalence of metabolic syndrome by IDF criteria is underdiagnosis in men and over-diagnosis in women compared to the Japanese criteria. Japanese cutoff point is calculated by the computed tomography (CT) scan data in which 100 cm2 abdominal fat area corresponds to nearly 100 cm WC. The standardization of diagnostic criteria is important to compare the efficacy of intervention and prevention of diseases between countries.
References
Watanabe S, Mizuno S, Hirakawa A. Effects of brown rice on obesity: GENKI Study I (cross sectional epidemiological study.) J Obesity Chronic Dis. 2018; 2(1): 12-19. doi: 10.17756/jocd.2018-013
Poirier P, Giles TD, Bray GA, et al. Obesity and cardiovascu-lar disease: Pathophysiology, evaluation, and effect of weight loss. Arterioscler Thromb Vasc Biol. 2006; 26: 968-976. doi: 10.1161/01. ATV.0000216787.85457.f3 6 Nakade M, et al.
Ford ES, Williamson DF, Liu S. Weight change and diabetes incidence: Findings from a national cohort of US adults. Am J Epidemiol. 1997; 146(3): 214-222. doi: 10.1093/oxfordjournals.aje. a009256
Zimmet P, Magliano D, Matsuzawa Y, Alberti G, Shaw J. The metabolic syndrome: A global public health problem and a new definition. J Atherosclerosis Thromb. 2005; 12(6): 295-300. doi: 10.5551/jat.12.295
Matsuzawa Y. Pathophysiology and molecular mecha-nisms of visceral fat syndrome: The Japanese experience. Diabetes Metab Rev. 1997; 13(1): 3-13. doi: 10.1002/(sici)1099- 0895(199703)13:1<3::aid-dmr178>3.0.co;2-n
Watanabe S. Waist circumference in the diagnosis of metabol-ic syndrome: Debate and solution. Ann Nutr Food Sci. 2018; 2(3): 1022.
Examination Committee of Criteria for ‘Obesity Disease’ in Ja-pan; Japan Society for the Study of Obesity. New criteria for ‘obe-sity disease’ in Japan. Circ J. 2002; 66(11): 987-992.
The IDF consensus worldwide definition of the metablolic syn-drome. Volume 2005. International Diabetes Federation. 2005.
Wing RR, Lang W, Wadden TA, et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011; 34(7): 1481-1486. doi: 10.2337/dc10-2415
Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002; 346(6): 393-403. doi: 10.1056/ NEJMoa012512
Watanabe S, Morita A, Aiba N, et al. Study design of the SAKU Control Obesity Program (SCOP). Anti-aging Med. 2007; 4(2): 70- 71. doi: 10.3793/jaam.4.70
Morita A, Ohmori Y, Suzuki N, Ide N, Morioka M, et al. An-thropometric and clinical findings in obese Japanese: The Saku Control Obesity Program (SCOP). Anti-aging medicine. 2008; 5(1): 13-16. doi: 10.3793/jaam.5.13
Nakade M, Aiba N, Suda N, et al. Behavioral change during weight loss program and one-year follow-up: Saku Control Obesity Program (SCOP) in Japan. Asia Pac J Clin Nutr. 2012; 21(1): 22-34.
Watanabe S. Population-based strategy for preventing diabetes and its complications. Diabetes Res Open J. 2018; 4(1): e1-e4. doi: 1 0.17140/DROJ-4-e011
Nakade M, Aiba N, Morita A, et al. Associations of waist-to-height ratio with various emotional and irregular eating, and mak-ing environment to promote eating in Japanese adults: The Saku Original Research | Volume 5 | Number 1| Cohort Study. Diabetes Res Open J. 2017; 3(2): 20-30. doi: 10.17140/ DROJ-3-132
Watanabe S, Tsugane S, Sobue T, Konishi M, Baba S. Study design and organization of the JPHC study. Japan public health center-based prospective study on cancer and cardiovascular dis-eases. J Epidemiol. 2001; 11 (6 Suppl): S3-S7.
Kawashima N, Watanabe S, Morita A, et al. Changes of fat vol-ume and adipocytokines by the randomized intervention program for obesity control program (SCOP). Diabetes Res Open J. 2015; 1(5): 136-146. doi: 10.17140/ DROJ-1-122
Matsuzawa Y. Specific health guidance, the nationawide lifestyle intervention program targeting metabolic syndrome, seems to be successful in Japan. J Atheroscler Thromb. 2018; 25(4): 304-305. doi: 10.5551/jat.ED092
Matsuzawa Y, Funahashi T, Nakamura T. Molecular mecha-Submit your article to this journal | https://openventio.org/submit-manuscript/ Original Research | Volume 5 | Number 1| Nakade M, et al. nism of metabolic syndrome X: Contribution of adipocytokines adipocyte-derived bioactive substances. Ann N Y Acad Sci. 1999; 892: 146-154. doi: 10.1111/j.1749-6632.1999.tb07793.x
Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999; 257(1): 79-83. doi: 10.1006/bbrc.1999.0255
Cnop M, Havel PJ, Utzschneider KM, Carr DB, Sinha MK, et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: Evidence for independent roles of age and sex. Diabetologia. 2003; 46(4): 459-469. doi: 10.1007/ s00125-003-1074-z
Tsushita K, Hosler AS, Miura K, et al. Rationale and descrip-tive analysis of specific health guidance: The national wide lifestyle intervention program 2010 targeting metabolic syndrome in Japan. J Atheroscler Thromb. 2018; 25(4): 308-322. doi: 10.5551/jat.4
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Diabetes Research (DR) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.
